Stem Cell Therapeutics Corp. Confirms Receipt of FDA Minutes

   Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SSS" or "Stem Cell Therapeutics") is pleased to announce that it has received the minutes from the FDA meeting of December 20, 2010. The purpose of that meeting was to present data from the NTx®-265 Phase I and Phase II studies to obtain medical, safety and statistical input about a planned pivotal study design.

Management is encouraged that the FDA minutes confirm their understanding of the discussions during the meeting.

Management is currently reviewing the minutes and incorporating them into the ongoing planning and design of another NTx®-265 trial. The next steps for this pivotal trial will include finalizing the protocol, planning the execution of the trial, determining appropriate financing and evaluating feasibility. Further details about the planned trial will be announced once they are available.

This news release shall not constitute an offer to sell nor the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as stroke, traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Stem Cell Therapeutics Corp. Allen Davidoff, PhD CSO 403-245-5495 ext.226 [e-mail] Stem Cell Therapeutics Corp. Michael Cook CFO 403-245-5495 ext. 229 [e-mail] Stem Cell Therapeutics Corp. Angelika Goncalves DaSilva Operations Manager 403-245-5495 ext. 230 [e-mail] www.stemcellthera.com